|
1
|
Yager JD and Davidson NE: Estrogen
carcinogenesis in breast cancer. N Engl J Med. 354:270–282. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Buteau-Lozano H, Ancelin M, Lardeux B,
Milanini J and Perrot-Applanat M: Transcriptional regulation of
vascular endothelial growth factor by estradiol and tamoxifen in
breast cancer cells: a complex interplay between estrogen receptors
alpha and beta. Cancer Res. 62:4977–4984. 2002.
|
|
3
|
Arruvito L, Sanz M, Banham AH and Fainboim
L: Expansion of CD4+CD25+ and FOXP3+ regulatory T cells during the
follicular phase of the menstrual cycle: implications for human
reproduction. J Immunol. 178:2572–2578. 2007.
|
|
4
|
Billingham RE, Brent L and Medawar PB:
Actively acquired tolerance of foreign cells. Nature. 172:603–606.
1953. View
Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stassen M, Jonuleit H, Müller C, Klein M,
Richter C, Bopp T, Schmitt S and Schmitt E: Differential regulatory
capacity of CD25+ T regulatory cells and preactivated CD25+ T
regulatory cells on development, functional activation, and
proliferation of Th2 cells. J Immunol. 173:267–274. 2004.
|
|
6
|
Polanczyk MJ, Carson BD, Subramanian S,
Afentoulis M, Vandenbark AA, Ziegler SF and Offner H: Cutting edge:
estrogen drives expansion of the CD4+CD25+ regulatory T cell
compartment. J Immunol. 173:2227–2230. 2004.PubMed/NCBI
|
|
7
|
Wu Y, Zhong Z, Huber J, Bassi R, Finnerty
B, Corcoran E, Li H, Navarro E, Balderes P, Jimenez X, Koo H,
Mangalampalli VR, Ludwig DL, Tonra JR and Hicklin DJ: Anti-vascular
endothelial growth factor receptor-1 antagonist antibody as a
therapeutic agent for cancer. Clin Cancer Res. 12:6573–6584. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yamamoto Y, Toi M, Kondo S, Matsumoto T,
Suzuki H, Kitamura M, Tsuruta K, Taniguchi T, Okamoto A, Mori T,
Yoshida M, Ikeda T and Tominaga T: Concentrations of vascular
endothelial growth factor in the sera of normal controls and cancer
patients. Clin Cancer Res. 2:821–826. 1996.PubMed/NCBI
|
|
9
|
Lissoni P, Fugamalli L, Malugani F,
Ardizzoia A, Secondino S, Tancini G and Gardani GS: Chemotherapy
and angiogenesis in advanced cancer: vascular endothelial growth
factor (VEGF) decline as predictor of disease control during Taxol
therapy in metastatic breast cancer. Int J Biol Markers.
15:308–311. 2000.
|
|
10
|
Bates GJ, Fox SB, Han C, Leek RD, Garcia
JF, Harris AL and Banham AH: Quantification of regulatory T cells
enables the identification of high-risk breast cancer patients and
those at risk of late relapse. J Clin Oncol. 24:5373–5380. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Recchia F, Saggio G, Amiconi G, Di Blasio
A, Cesta A, Candeloro G and Rea S: Gonadotropin-releasing hormone
analogues added to adjuvant chemotherapy protect ovarian function
and improve clinical outcomes in young women with early breast
carcinoma. Cancer. 106:514–523. 2006. View Article : Google Scholar
|
|
12
|
Recchia F, Nuzzo A, Lalli A, De Filippis S
and Torchio P: Activity of standard-dose carboplatin,
cyclophosphamide, and etoposide in patients with metastatic breast
cancer with previous exposure to anthracyclines. Am J Clin Oncol.
20:166–168. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Recchia F, De Fillipis S, Piccinini M and
Rea S: High-dose carboplatin, cyclophosphamide, etoposide with
hematological growth factors, without stem cell support in patients
with advanced cancer. Anticancer Res. 23:4141–4147. 2003.PubMed/NCBI
|
|
14
|
Recchia F, Saggio G, Cesta A, Alesse E,
Gallo R, Necozione S and Rea S: Phase II randomized study of
interleukin-2 with or without 13-cis retinoic acid as maintenance
therapy in patients with advanced cancer responsive to
chemotherapy. Anticancer Res. 25:3149–3157. 2005.PubMed/NCBI
|
|
15
|
Simon R: Optimal two-stage designs for
phase II clinical trials. Control Clin Trials. 10:1–10. 1989.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kaplan EL and Meier P: Nonparametric
estimation from incomplete observations. J Am Stat Assoc.
53:457–481. 1958. View Article : Google Scholar
|
|
17
|
Brenner H and Hakulinen T: Are patients
diagnosed with breast cancer before age 50 years ever cured? J Clin
Oncol. 22:432–438. 2004.PubMed/NCBI
|
|
18
|
Beatson GT: On the treatment of inoperable
cases of carcinoma of the mamma: suggestions for a new method of
treatment with illustrative cases. Lancet. ii:104–107. 1896.
View Article : Google Scholar
|
|
19
|
No authors listed:. Systematic treatment
of early breast cancer by hormonal, cytotoxic, or immune therapy:
133 randomised trials involving 31,000 recurrences and 24,000
deaths among 75,000 women. Early Breast Cancer Trialists’
Collaborative Group Lancet. 339:1–15. 1992.
|
|
20
|
Goel S, Sharma R, Hamilton A and Beith J:
LHRH agonists for adjuvant therapy of early breast cancer in
premenopausal women. Cochrane Database Syst Rev.
4:CD0045622009.
|
|
21
|
Early Breast Cancer Trialists’ Cooperative
Group (EBCTCG): Effects of chemotherapy and hormonal therapy for
early breast cancer on recurrence and 15-year survival: an overview
of the randomised trials. Lancet. 365:1687–1717. 2005.PubMed/NCBI
|
|
22
|
Eliassen AH, Missmer SA, Tworoger SS,
Spiegelman D, Barbieri RL, Dowsett M and Hankinson SE: Endogenous
steroid hormone concentrations and risk of breast cancer among
premenopausal women. J Natl Cancer Inst. 98:1406–1415. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anders CK, Hsu DS, Broadwater G, Acharya
CR, Foekens JA, Zhang Y, Wang Y, Marcom PK, Marks JR, Febbo PG,
Nevins JR, Potti A and Blackwell KL: Young age at diagnosis
correlates with worse prognosis and defines a subset of breast
cancers with shared patterns of gene expression. J Clin Oncol.
26:3324–3330. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Elkin M, Orgel A and Kleinman HK: An
angiogenic switch in breast cancer involves estrogen and soluble
vascular endothelial growth factor receptor 1. J Natl Cancer Inst.
96:875–878. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Laurentiis M, Cancello G, D’Agostino D,
Giuliano M, Giordano A, Montagna E, Lauria R, Forestieri V,
Esposito A, Silvestro L, Pennacchio R, Criscitiello C, Montanino A,
Limite G, Bianco AR and De Placido S: Taxane-based combinations as
adjuvant chemotherapy of early breast cancer: a meta-analysis of
randomized trials. J Clin Oncol. 26:44–53. 2008.PubMed/NCBI
|
|
26
|
Toledano A, Azria D, Garaud P, Fourquet A,
Serin D, Bosset JF, Miny-Buffet J, Favre A, Le Floch O and Calais
G: Phase III trial of concurrent or sequential adjuvant
chemoradiotherapy after conservative surgery for early-stage breast
cancer: final results of the ARCOSEIN trial. J Clin Oncol.
25:405–410. 2007. View Article : Google Scholar
|
|
27
|
Detre S, Salter J, Barnes DM, Riddler S,
Hills M, Johnston SR, Gillett C, A’Hern R and Dowsett M:
Time-related effects of estrogen withdrawal on proliferation- and
cell death-related events in MCF-7 xenografts. Int J Cancer.
81:309–313. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Linderholm B, Grankvist K, Wilking N,
Johansson M, Tavelin B and Henriksson R: Correlation of vascular
endothelial growth factor content with recurrences, survival, and
first relapse site in primary node-positive breast carcinoma after
adjuvant treatment. J Clin Oncol. 18:1423–1431. 2000.
|
|
29
|
Nakamura Y, Yasuoka H, Tsujimoto M, Yang
Q, Imabun S, Nakahara M, Nakao K, Nakamura M, Mori I and Kakudo K:
Prognostic significance of vascular endothelial growth factor D in
breast carcinoma with long-term follow-up. Clin Cancer Res.
9:716–721. 2003.PubMed/NCBI
|
|
30
|
Eppenberger U, Kueng W, Schlaeppi JM,
Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K,
Litschgi M, Schmitt M, Foekens JA and Eppenberger-Castori S:
Markers of tumour angiogenesis and proteolysis independently define
high- and low-risk subsets of node-negative breast cancer patients.
J Clin Oncol. 16:3129–3136. 1998.PubMed/NCBI
|
|
31
|
Salven P, Mänpää H, Orpana A, Alitalo K
and Joensuu H: Serum vascular endothelial growth factor is often
elevated in disseminated cancer. Clin Cancer Res. 5:647–651.
1997.PubMed/NCBI
|
|
32
|
Gabrilovich DI, Chen HL, Girgis KR,
Cunnigham HT, Meny GM, Nadaf S, Kavanaugh D and Carbone DP:
Production of vascular endothelial growth factor by human tumors
inhibits the functional maturation of dentritic cells. Nat Med.
2:1096–1103. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pidgeon GP, Barr MP, Harmey JH, Foley DA
and Bouchier-Hayes DJ: Vascular endothelial growth factor (VEGF)
upregulates BCL-2 and inhibits apoptosis in human and murine
mammary adenocarcinoma cells. Br J Cancer. 85:273–278. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Merlo A, Casalini P, Carcangiu ML,
Malventano C, Triulzi T, Mènard S, Tagliabue E and Balsari A: FOXP3
expression and overall survival in breast cancer. J Clin Oncol.
27:1746–1752. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gupta S, Joshi K, Wig JD and Arora SK:
Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its
association with clinicopathologic parameters and angiogenesis.
Acta Oncol. 46:792–797. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Decker T, Fischer G, Bücke W, Bücke P,
Stotz F, Grüneberger A, Gropp-Meier M, Wiedemann G, Pfeiffer C,
Peschel C and Götze K: Increased number of regulatory T cells
(T-regs) in the peripheral blood of patients with
Her-2/neu-positive early breast cancer. J Cancer Res Clin Oncol.
138:1945–1950. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Jonat W, Kaufmann M, Sauerbrei W, Blamey
R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart
A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M and
Lisboa B; Zoladex Early Breast Cancer Research Association Study:
Goserelin versus cyclophosphamide, methotrexate, and fluorouracil
as adjuvant therapy in premenopausal patients with node-positive
breast cancer: The Zoladex Early Breast Cancer Research Association
Study. J Clin Oncol. 20:4628–4635. 2002. View Article : Google Scholar
|
|
38
|
Swain SM, Jeong JH, Geyer CE Jr,
Costantino JP, Pajon ER, Fehrenbacher L, Atkins JN, Polikoff J,
Vogel VG, Erban JK, Rastogi P, Livingston RB, Perez EA, Mamounas
EP, Land SR, Ganz PA and Wolmark N: Longer therapy, iatrogenic
amenorrhea, and survival in early breast cancer. N Engl J Med.
362:2053–2065. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Park IH, Han HS, Lee H, Lee KS, Kang HS,
Lee S, Kim SW, Jung S and Ro J: Resumption or persistence of
menstruation after cytotoxic chemotherapy is a prognostic factor
for poor disease-free survival in premenopausal patients with early
breast cancer. Ann Oncol. 23:2283–2289. 2012. View Article : Google Scholar : PubMed/NCBI
|
